279 related articles for article (PubMed ID: 26581076)
1. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
Chatterjee C; Kubo K; Pingali V
J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
[TBL] [Abstract][Full Text] [Related]
2. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
3. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
Lexchin J
Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005
[TBL] [Abstract][Full Text] [Related]
4. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
5. Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India.
Chaudhuri S; Goldberg PK; Jia P
Am Econ Rev; 2006 Dec; 96(5):1477-514. PubMed ID: 29135209
[TBL] [Abstract][Full Text] [Related]
6. Compulsory licensing of patents in India.
Chaudhry R
Pharm Pat Anal; 2016 Sep; 5(6):401-406. PubMed ID: 27805847
[TBL] [Abstract][Full Text] [Related]
7. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
8. Patent litigation in India continues to throw up new challenges.
Reddy Thikkavarapu P
Pharm Pat Anal; 2016 Jul; 5(4):211-6. PubMed ID: 27348790
[TBL] [Abstract][Full Text] [Related]
9. The Chinese medicines market: moving towards a market system?
Huttin C
Health Policy; 1994 Sep; 29(3):247-59. PubMed ID: 10138727
[TBL] [Abstract][Full Text] [Related]
10. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis.
Shih YC; Prasad M; Luce BR
Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413
[TBL] [Abstract][Full Text] [Related]
11. Patent protection for medical technologies: why some and not others?
Melzer D
Lancet; 1998 Feb; 351(9101):518-9. PubMed ID: 9482467
[No Abstract] [Full Text] [Related]
12. [Development costs, regulation and audit in the German SHI Drug Sector].
Kamp F; Walter P; Bücheler R
Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
[No Abstract] [Full Text] [Related]
13. Secondary patents in the pharmaceutical industry: missing the wood for the trees?
Kiran S; Kulkarni M
Expert Opin Ther Pat; 2018 Mar; 28(3):241-250. PubMed ID: 29298119
[TBL] [Abstract][Full Text] [Related]
14. An economic justification for open access to essential medicine patents in developing countries.
Flynn S; Hollis A; Palmedo M
J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066
[TBL] [Abstract][Full Text] [Related]
15. Affordability versus innovation: Is compulsory licensing the solution?
Pandey E; Paul SB
Int J Risk Saf Med; 2019; 30(4):233-247. PubMed ID: 31658067
[TBL] [Abstract][Full Text] [Related]
16. The welfare impact of parallel imports: a structural approach applied to the German market for oral anti-diabetics.
Duso T; Herr A; Suppliet M
Health Econ; 2014 Sep; 23(9):1036-57. PubMed ID: 25139795
[TBL] [Abstract][Full Text] [Related]
17. Compulsory licensing and access to drugs.
Stavropoulou C; Valletti T
Eur J Health Econ; 2015 Jan; 16(1):83-94. PubMed ID: 24408475
[TBL] [Abstract][Full Text] [Related]
18. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
[TBL] [Abstract][Full Text] [Related]
19. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
Tang WL
Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
[TBL] [Abstract][Full Text] [Related]
20. Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
Xu Z; Chen W
Pak J Pharm Sci; 2017 May; 30(3(Special)):1081-1087. PubMed ID: 28671085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
